Company intelligence / Profile preview

Vimela Therapeutics

Ownership: Private
Development stage: Other

Overview

Vimela Therapeutics is developing a peptide-based topical immunotherapy for vitiligo; its lead asset VIM-004 gel entered a phase Ib/IIa proof-of-concept, double-blind, placebo-controlled study in 2025 to evaluate safety, tolerability and preliminary efficacy in vitiligo patients.[2]

Therapeutic areas: Dermatology
Modalities: Peptides
Industry: Biotech

Drug pipeline

1 asset

VIM-004 (afamelanotide)

Unknown

Partnerships

Alys Pharmaceuticals (aggregation/ownership and pipeline integration)[2][3]

Beyond the preview

Go deeper on Vimela Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vimela Therapeutics.